Summary: We measured the activity of angiotensin converting enzyme (EC 3.4.15.1) in urine samples from normal subjects and patients with nephrotic syndrome and chronic glomerulonephritis. Urinary excretion of angiotensin converting enzyme in patients with nephrotic syndrome (1.58 ± 0.50 (SD) units/day; n = 15) and chronic glomerulonephritis (1.01 ± 0.45 units/day; n = 12) was significantly increased compared with normal subjects (0.38 ± 0.10 units/day; n = 18). It was demonstrated that a high molecular weight form of the enzyme (more than 400000) was mainly excreted in urines from patients with nephrotic syndrome. After trypsin treatment, this form was altered to a low molecular weight form (290000). These two different forms of urinary angiotensin converting enzyme were compared with the enzyme purified from human kidney, and found to be identical with respect to K m value (2 mmol/l) 5 pH Optimum (pH 8.3), Chloride ion dependency (0.8 mol/1), inhibitory effect of captopril (I 50 , 21 nmol/1), and behaviour tpwärds antiserum to human kidney angiotensin converting enzyme.
Increased Urinary Excretion of Angiotensin Converting Enzyme in Patients with Renal Diseases
Summary: We measured the activity of angiotensin converting enzyme (EC 3.4.15.1) in urine samples from normal subjects and patients with nephrotic syndrome and chronic glomerulonephritis. Urinary excretion of angiotensin converting enzyme in patients with nephrotic syndrome (1.58 ± 0.50 (SD) units/day; n = 15) and chronic glomerulonephritis (1.01 ± 0.45 units/day; n = 12) was significantly increased compared with normal subjects (0.38 ± 0.10 units/day; n = 18). It was demonstrated that a high molecular weight form of the enzyme (more than 400000) was mainly excreted in urines from patients with nephrotic syndrome. After trypsin treatment, this form was altered to a low molecular weight form (290000). These two different forms of urinary angiotensin converting enzyme were compared with the enzyme purified from human kidney, and found to be identical with respect to K m value (2 mmol/l) 5 pH Optimum (pH 8.3), Chloride ion dependency (0.8 mol/1), inhibitory effect of captopril (I 50 , 21 nmol/1), and behaviour tpwärds antiserum to human kidney angiotensin converting enzyme. 
Erhöhte Ausscheidung von Angiotensin Converting Enzyme im Harn bei Patienten mit Nierenerkrankungen

Introductipn
Angiotensin converting enzyme (EC 3.4.15.1) converts angiotensin I to angiotensin II by releasing the C-terminal dipeptide (1) . It also inactivates brädykinin and is identical with kininase II (2, 3). Ward et al. (4) and Caldwell et al. (5) have reported that the brush border membrane of renal proximal tubules contains a high " concentration of angiotensin converting enzyme. We have reported that angiotensin converting enzyme is excreted in normal human urine and that urinary excretion of the enzyme is related to sodium excretion (6) . In this study, we measured the activity of urinary angiotensin converting enzyme in patients with nephrotic syndrome and chronic glomerulonephritis and found that they excreted significantly higher angiotensin converting enzyme than normal subjects. The character of the enzyme excreted in urine under pathological conditions was studied.
Materials and Methods
Materials
Hippuryl-£-histidyl-Z,-leucine (hippuryl-His-Leu) was purchased from Protein Research Foundation, Minoh, Osaka, Japan. The molecular weight marker kit was from Boehringer Mannheim GmbH, West Germany. Sephadex G-200 was from Pharmacia Fine Chemicals AB, Uppsala, Sweden. Trypsin (11000 -benzoyi-L-arginine ethyl ester (BAEE) units/mg protein) was from Sigma Chemical Co., St. Louis, MO., U.S.A. Captopril (INN) was kindly supplied from Sankyo Co., Ltd., Tokyo, Japan.
Probands
Normal subjects and patients with renal diseases: 18 normal subjects (male, n -10; female, n = 8; mean age, 45 ± 16a (SD)) were medical staffs and volunteers. Sodium was not restricted. Patients with nephrotic syndrome and chronic glomeruloncphritis admittcd in our clinic were placed on a diet containing 5.8-7 g sodium Chloride per day and received no drugs during the examination. 15 nephrotic patients (male, n = 10; female, n = 5; mcan age, 36 ± 19a) were diagnosed according to the follo\ving criteria; 0340-076X/82/0020-0473$02.00 © by Walter de Gruyter & Co. -Berlin · New York morc than 3.5 g of daily proteinuria, hypoalbuminaemia Qess than 3 g/dl), hyperlipidacmia (total cholesterol, more than 350 mg/dl) and oedema. The mean urea nitrogen and creatinine concentrations in serum were 19.6 ± 9.8 (SD) mg/dl (12-44 mg/ dl) and 1.37 ± 0.90 mg/dl (0.7-4.4 mg/dl), respectively. In 15 nephrotic patients, 7 patients had a renal biopsy which revealed histopathological features (minimal change, n = 3; membranous nephropathy, n = 3; membranoproliferative glomerulonephritis, n=l). 12 patients \vith chronic glomerulonephritis (male, n = 6; female, n = 6; mean age, 35 ± 14a) were diagnosed according to the following criteria; persistent proteinuria (more than l year), casts, especially erythrocyte casts, microscopic haematuria, exclusion of Collagen diseases, diabetic and gouty nephropathy, essential hypertension, pyelonephritis, orthostatic proteinuria and toxic nephropathy. The mean serum urea nitrogen and creatinine concentrations were 27.9 ± 22.3 mg/dl (12-75 mg/dl) and 2.38 ± 2,18 mg/dl (0.7-6.2 mg/dl), respectively. 5 of 12 patients had a renal biopsy which confirmed the histological diagnosis (membranous nephropathy, n = 4; membranoproliferative glomerulonephritis, n = 1).
Urine samples 24 h urines were collected at 4 °C. Urine samples (50 ml) were adjusted to pH 7.0 with l mol/1 NaOH. The sample was centrifuged at 3000 min~\ for 20 min at 4 °C. The supematant was fractionated \vith 3.14 mol/1 ammonium sulfate. The precipitate was dissoived in 8 ml and dialysed against 10 mmol/1 phosphate buffer, pH 7.8. The approximately 5-fold concentrated sample was again centrifuged at 8000 min" 1 at 4 °C and the supematant was used for the determination of the enzymic activity. During the preparation of the enzyme material, the recovery of enzymic activity was approximately 70%.
Assay of angiotensin converting enzyme activity Angiotensin converting enzyme activity was measured by the modified method of Cushman & Cheung (7). The total l ml assay mixture contained 80 mmol/1 borate-sodium carbonate buffer, pH 7.8, 2 mmol/1 hippuryl-His-Leu and 0.2 ml concentrated urine sample. The assay mixture was incubated at 37 °C for 120 min and the reaction was stopped by adding 0.5 ml of l mol/1 HC1. The hippuric acid was extracted with 3 ml of ethyl acetate by vortex mixing for 20 s. Two ml of the extract was evaporated and dried, and then 2 ml of distilled water was added. The concentration of hippuric acid was determined by measuring the absorbance at 228 nm against a zero time blank prepared by adding 0.5 ml of l mol/1 HQ to the assay mixture before the reaction. One unit of the enzymic activity was defined s that amount of the enzyme which hydrolysed l μπιοΐ/πήη of hippuryl-His-Leu at 37 °C under the described condition.
Gel filtration Gel Filtration of a column of Sephadex G-200 (2.6 X 90 cm) for the determination of the apparent molecular weight was carried out by the method described previo sly (8) .
Other procedures
The concentration of sodium in the urine sample was measured by a flame photometer (Beckman, Klina Flame). Protein was measured by the method of Lowry et al. (9) . Anti-human kidney angiotensin converting enzyme antiserum used in this study was described previo sly (10). 5 μΐ of the antiserum inhibited half the catalytic activity of l μ δ of pure enzyme protein (0.1 U).
Statistical evaluation
Mean values were expressed s the mean ± SD. Student'* t test 
Results
Urinary angiotensin converting enzyme activity
Urinary angiotensin converting enzyme activities in normal subjects (n = 18) and patients with nephrotic syndrome (n = 15) and chronic glomerulonephritis (n = 12) were 0.38 ±0.10, 1.58±0.50and 1.01 ±0.45 units/day (x ± s), respectively ( fig. 1) . Uririary angiotensin cpnverting enzyme activities were signific ntly higher in patients with nephrotic syndrome (p < 0.001) and chronic glomerulonephritis (p < 0.005) than that of normal subjects. There was no relati riship between the enzymic activity and the concentration of sodium excretion in patients with nephrotic syndrome (r = 0.13, p > 0.2) and chronic glomerulonephritis (r = -0.38, 0.2 >p> 0.1). Furthermore, there was no signiflcant correlation between angiotensin converting enzyme activity and protein amourit excreted in the urine (r = 0.36, p > 0.1). Angiotensin converting enzyme activities in urine samples from normal subjects (n ^ 18) and patients with nephrotic syndrome (n = 15) and chronic glomerulonephritis (n = 12). 200 μΐ of the urine samples fractionated with 3.14 mol/1 ammonium sulfate was assayedi with 2 rnmol/1 hippuryl-His-Leu s Substrate. The enzymic actjvity was expressed s units/day. Bars indicate the mean ± SD. *p<0.005; **p<0.001
Multiple forms of angiotensin converting enzyme in human urine
Fresh urine samples (150 ml) from 5 normal subjects and 4 nephrotic patients were dialysed against 10 mmol/1 phosphate buffer, pH 7,8 at 4 °C ovenught. Each sample (3-4 ml) concentrated with Arhicon PM 10 membrane was applied to a column of Sephadex G-200 (2.6 X 90 cm). Fractions of 3.25 ml were collected. Typical profiles from normal subjects and patients with nephrotic syndrome are shown in figure 2. •-o Enzymic activity in the urine from one normal subject. o-o Enzymic activity in the urine from one nephrotic patient.
The enzymic activities appeared in fractions of No. 42-48 (high molecular weight) and No. 52-63 (low molecular weight). The ratios of the enzymic activity of high molfecular weight form (M T > 400000) against that of low molecular weight form (Λ/ Γ = 290000) in 5 normal subjects and 4 nephrotic patients were 1.5 ± 0.45 and 3.8 ± 1.4, respectively. After trypsin treatment (l mg trypsin/10 ing of protein in the enzyme material) for 2 h at 37 °C, only the low molecular weight form appeared in gel filtration on Sephadex G-200 (Fig. 3) .
Properties oflow molecular weight and high molecular weight forms of urinary angiotensin converting enzyme
Low molecular weight and high molecular weight fprms Of urinary angiotensin converting enzyme from normal subjects were partially purified by DEAE-cellulose column chromatography and Sephadex G-200 gel filtration and used s a sample for the following experiments. pH optimum: The pH dependence of hydrolysis of hippuryl-His-Leu in 80 mmol/1 borate^sodium carbonate buffer, between pH 6 and 9 with low molecular weight and high molecular weight forms of urinary angiotensin converting enzyme, showed a maximum around pH 8.3, which corresponded with that of the pure human kidney angiotensin converting enzyme (10). Chloride ion dependency: The reactions of low molecular weight and high molecular weight forms of angiotensin converting enzyme were carried out in the presence of various concentrations of NaCl (0.1 -l .2 mol/1). The highest activity in both forms of angiotensin converting enzyme was observed at the concentration of 0.8 mol/1 NaCl. The purified human kidney angiotensin converting enzyme showed the same result. •-· Enzymic activity in non-treated urine sample, o-o Enzymic activity in trypsin-treated urine sample.
Effects of captopril and rabbit antiserum to human kidney angiotensin converting enzyme: Both enzymic activities oflow molecular weight and high molecular weight forms were inhibited completely by l μπιοΐ/ΐ captopril. I 50 of captopril was identical for low and high molecular weight forms of urinary angiotensin converting enzyme (21 nmol/1). Low molecular weight and high molecular weight forms of urinary angiotensin converting enzyme were incubated with varying amounts of anti-human kidney angiotensin converting enzyme antiserum in 80 mmol/I borate-sodium carbonate buffer, pH 7.8 at 37 °C for 30 min and the remaining enzymic activities of both forms of angiotensin converting enzyme (each 0.1 unit) were inhibited similarly. Five μΐ of the antiserum inhibited about 50% of the activities oflow and high molecular weight forms of urinary angiotensin converting enzyme.
Discussion
Recently Baggio et al. (l 1) reported that urinary angiotensin converting enzyme was significantly increased in patients affected by upper urinary tract infection and neplirolithiasis. Partially purified urinary angiotensin converting enzyme showed the highest activity at a NaCl concentration of 0.8 mol/1, but we measured the activity in urine samples in 0.3 mol/1 NaCl to avoid the interference of turbidity sometimes seen at 0.8 mol/1 NaCl. We demonstrated that angiotensin converting enzyme activity in urine was significantly higher in patients with nephrotic syndrome and chronic glomerulonephritis than in normal subjects. However, there was no significant relationship between urinary angiotensin converting enzyme activity and the amount of protein excreted in the urine. In nephrotic patients, an increase in urinary angiotensin converting enzyme activity was due mainly to an increased release of the high molecular weight form of angiotensin converting enzyme. This high molecular weight form of angiotensin converting enzyme cannottie detected in serum (12) . The high molecular weight form of urinary angiotensin converting enzyme changed to the low molecular form when treated with trypsin. The molecular weight of the low molecular weight form of the enzyme was the same äs those of human serum angiotensin converting enzyme (12) and angiotensin converting enzymes from human kidney (10) and human lung (13), both of which were solubilized from membrane fractions with trypsin. Properties of both low and high molecular weight forms of urinary angiotensin converting enzyme were identicäl with those of the enzyme purified from human kidney with respect to pH Optimum, K m value, Chloride ion dependency and Inhibition by captopril or antiserum to human kidney angiotensin converting enzyme.
Various enzymes are present in urine äs a result of their direct release from the kidney into the urine (14) . In patients with chronic glomerulonephritis with or without nephrotic syndrome, membrane-bound enzymes specific for the luminal portion öf proximal epithelia were excreted in the urine at an increased rate (15).
Hiwada et al. (16) have reported that aminopeptidase N (EC 3.4.11.2) in urines from nephrotic children is significantly higher than that from normal children. The high molecular weight form of aminopeptidase N was identicäl with the enzyme originating from the brush border of tubular cells. The ratio of Kij*h molecular weight form to low molecular weight form of uriiiary aminopeptidase N was almost unchanged in urines from normal and nephrotic children. On the other hand, the ratio of high mplecular weight iö low molecular weight forms of urinary angiotensin converting enzyme was increased in nephrotic patients compared with normal subjects. 1t is suggested that urinary angiotensin converting enzyme is released from the kidney into urine äs a high molecular weight form and this high molecular weight form is altered in paft tö the low molecular weight form by trypsin-like enzyme(s) in urine. Both angio tensin converting enzyme and aminopeptidase N are membrane-bound enzymes. The mechanism of release of angiotensin converting enzyme and aminopeptidase N from the brush border of tubular cells seems to be different.
We found a significant correlation between sodium and angiotensin converting enzyme excretion in normal subjects (6) . In nephrotic syndrome and chronic glomerulonephritis, however, such a relationship between sodium and angiotensin converting enzyme excretion was not observed, and the high molecular weight form of angiotensin converting enzyme was increased more than the low molecülar weight form. This rneans that increased urinary angiotensin converting enzyme excretion under pathologic conditions mainly depends pn the damage of proximal tübular cells äs suggested by Scherberich & Mondorf (15) , resultirig ih'the loss of correlation between sodium and angiotensin converting enzyme excretion obserVed in normal subjects.
